209 related articles for article (PubMed ID: 32518548)
21. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
22. Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma.
Sano S; Asahi Y; Kamiyama T; Kakisaka T; Orimo T; Nagatsu A; Aiyama T; Kazui K; Shomura H; Ueki S; Sakamoto Y; Shirakawa C; Kamachi H; Sugino H; Mitsuhashi T; Taketomi A
Int Cancer Conf J; 2023 Jan; 12(1):7-13. PubMed ID: 36605836
[TBL] [Abstract][Full Text] [Related]
23. Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report.
Yang CH; Chen KT; Lin YS; Hsu CY; Ou YC; Tung MC
World J Clin Cases; 2020 Oct; 8(20):4883-4894. PubMed ID: 33195657
[TBL] [Abstract][Full Text] [Related]
24. Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma.
Hyogo Y; Kiyota N; Otsuki N; Goto S; Imamura Y; Chayahara N; Toyoda M; Nibu KI; Hyodo T; Hara S; Masuoka H; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Case Rep Oncol; 2018; 11(3):735-741. PubMed ID: 30519176
[TBL] [Abstract][Full Text] [Related]
25. Anaplastic Thyroid Carcinoma Treated with Lenvatinib.
Ohkubo JI; Takahashi A; Ikezaki S; Takenaga F; Ohkubo Y; Suzuki H
Kurume Med J; 2018 Feb; 64(1.2):29-33. PubMed ID: 29057760
[TBL] [Abstract][Full Text] [Related]
26. Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report.
Buenaventura DC; Vargas-Sierra H; Aristizabal-Henao N; Torres-Grajales JL; Aguilar-Londono C; Gutierrez-Restrepo J
Int J Endocrinol Metab; 2023 Jul; 21(3):e136900. PubMed ID: 38028246
[TBL] [Abstract][Full Text] [Related]
27. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report.
Yamazaki H; Masudo K; Kanada S; Inayama Y; Hayashi H; Fujii Y; Rino Y
Surg Case Rep; 2023 Mar; 9(1):38. PubMed ID: 36920674
[TBL] [Abstract][Full Text] [Related]
28. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma.
Yamazaki H; Iwasaki H; Suganuma N; Toda S; Masudo K; Nakayama H; Rino Y; Masuda M
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31600721
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma.
Masaki C; Sugino K; Saito N; Saito Y; Tanaka T; Ogimi Y; Maeda T; Osaku T; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2017 Aug; 64(8):819-826. PubMed ID: 28659544
[TBL] [Abstract][Full Text] [Related]
33. Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer.
Obata K; Sugitani I; Ebina A; Sugiura Y; Toda K; Takahashi S; Kawabata K
Int Cancer Conf J; 2016 Oct; 5(4):197-201. PubMed ID: 31149454
[TBL] [Abstract][Full Text] [Related]
34. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
Lorusso L; Pieruzzi L; Biagini A; Sabini E; Valerio L; Giani C; Passannanti P; Pontillo-Contillo B; Battaglia V; Mazzeo S; Molinaro E; Elisei R
Onco Targets Ther; 2016; 9():6467-6477. PubMed ID: 27799794
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report.
Latorre A; Fioretti AM; Giotta F; Lorusso V
Future Oncol; 2019 Aug; 15(24s):27-33. PubMed ID: 31393171
[TBL] [Abstract][Full Text] [Related]
38. Hurthle Cell Thyroid Carcinoma with Liver and Paraaortic Abdominal Nodal Metastasis: Progression on Sorafenib Therapy after Initial Disease Stabilization.
Loharkar S; Basu S
World J Nucl Med; 2023 Mar; 22(1):70-74. PubMed ID: 36923984
[TBL] [Abstract][Full Text] [Related]
39. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
40. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
